Literature DB >> 10697884

Italian Development Cooperation: the commitment for the struggle against malaria in Africa.

G Masala1, V Racalbuto, G Gentile, P Procacci.   

Abstract

The Italian Development Cooperation (DGCS) support the health reform process in Developing Countries, with the aim to provide populations in greatest need with access to decentralized health services. DGCS acts in close coordination with the donor community, United Nations' system and the World Bank, in agreement with sector-wide approach (SWAP) for health sector development. Since malaria control in endemic countries is a relevant component of the health system, DGCS is actively involved in the struggle against malaria in sub-Saharan Africa, supporting control activities and research capability strengthening. The following African countries are presently receiving bilateral support for antimalaria activities: Burkina Faso, Centre de Lutte contre le Paludisme in Ouagadougou; Ethiopia, community-based malaria control in Tigray; Eritrea, malaria control at national level in the framework of the Public Health and Rehabilitation Programme for Eritrea (PHARPE) initiative; Madagascar, malaria surveillance at national level; Tanzania, feasibility study for the support to the national malaria control programme. Support is provided by technical/financial assistance involving Italian academic and research institutions. On the multilateral channel, DGCS has provided regular contribution for WHO's work in malaria control and participates to the WHO Roll Back Malaria initiative. A new commitment to malaria is the trilateral joint scientific endeavour USA-Italy-Burkina Faso for the development and field testing of a candidate vaccine suitable for African populations.

Entities:  

Mesh:

Year:  1999        PMID: 10697884

Source DB:  PubMed          Journal:  Parassitologia        ISSN: 0048-2951


  1 in total

Review 1.  Italy's contribution to global health: the need for a paradigm shift.

Authors:  Eduardo Missoni; Fabrizio Tediosi; Guglielmo Pacileo; Lara Gautier
Journal:  Global Health       Date:  2014-04-06       Impact factor: 4.185

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.